iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray

NCT03192501 · tracked via the Priya Life Science China tracker

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Phase

Observational

Started

2017-07-01

Last updated

2024-06-25

Condition(s) studied

Lung CancerGene AbnormalityGene Product Sequence VariationCancer

Investigational drug(s) / intervention(s)

inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.

inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.: Choose appropriate targeted drugs according to NGS/IHC results.

Study summary

This study prospectively evaluates whether the use of iCAGES (integrated CAncer GEnome Score) tool in guiding the treatment of advanced cancers is superior to current standard care or IHC-guided therapy in progress free survival (PFS),overall survival (OS),and improvement of life quality.

Eligibility

Sex

ALL

Min age

18 Years

Max age

70 Years

Healthy volunteers

Inclusion Criteria: * Pathological and clinical diagnosis of recurrence / metastatic lung cancer or other advanced cancers. * There are PACS images available at the Second Affiliated Hospital of Guangzhou Medical University and the collaborated Hospitals. * The patient is informed consent and signed a written consent. Exclusion Criteria: * Age \> 70 or \<18 years old. * Previous history of malignant tumors. * Pregnant or lactating female patients. * Any serious concomitant disease that is expected to have an adverse effect on prognosis, including the heart disease that treatment is required, unsatisfactory controlled diabetes and psychiatric disorders.

Primary outcome measure(s)

PFS — 2 years
The PFS will be recorded during the follow up time.
OS — 2 years
The OS will be recorded during the follow up time.

Trial sites (1)

Facility	City	Region	Status
The Second Affiliated Hospital of Guangzhou Medical University	Guangzhou	Guangdong	Recruiting

More Second Affiliated Hospital of Guangzhou Medical University trials in China

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors Recruiting

Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus Recruiting

Y-90 SIRT for Unresectable HCC Larger Than 7cm Recruiting

Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT Recruiting

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors Recruiting

Other trials for the same condition

MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH) Active, not recruiting

A Phase II Clinical Study Evaluating the Effectiveness of Injectable NC527-X in Intraoperative Imaging for Patients With Solid Tumors Recruiting

Immunotherapy Treating GI Cancer Starting soon

Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors Recruiting

Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03192501 on ClinicalTrials.gov ↗ ← All trials in China